Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus (LGA-IRT).
The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.
A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 results compared to risankizumab (RKB) adults with active psoriatic arthritis (PsA). These are the preliminary, week 16, primary endpont results of a longer blinded head-to-head trial.
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if body weight reliably predicts drug exposure. It does not.
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
Does exercise or lifestyle modifications reduce the risk of getting rheumatoid arthritis (RA) or change those with early RA?
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study.
Have you ever seen multicentric reticulohistiocytosis? Don't worry, it's a rare non-Langerhans cell histiocytosis condition, characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and has only been described in fewer than 500 cases reported worldwide.
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
